Metabonomic changes from pancreatic intraepithelial neoplasia to pancreatic ductal adenocarcinoma in tissues from rats

Shi Wen,1,3 Zhishui Li,2,3 Jianghua Feng,2 Jianxi Bai,1 Xianchao Lin1 and Heguang Huang1

1Department of General Surgery, Fujian Medical University Union Hospital, Fuzhou; 2Department of Electronic Science, Fujian Provincial Key Laboratory of Plasma and Magnetic Resonance, Xiamen University, Xiamen, China

Key words
Biomarker, metabonomics, nuclear magnetic resonance, pancreatic cancer, pancreatic intraepithelial neoplasia

Correspondence
Heguang Huang, Department of General Surgery, Fujian Medical University Union Hospital, Fuzhou; Tel: +8613705947538; E-mail: hhuang2@aliyun.com and
Jianghua Feng, Department of Electronic Science, Fujian Provincial Key Laboratory of Plasma and Magnetic Resonance, Xiamen University, Xiamen, China; Tel: +86-592-2183301; Fax: +86-592-2189426; E-mail: jianghua.feng@xmu.edu.cn

Funding Information
United Fujian Provincial Health and Education Project for Tackling the Key Research (Grant/Award Number: “WKJ-FJ-10”), National Key Clinical Specialty Discipline Construction Program of China, Key Clinical Specialty Discipline Construction Program of Fujian, National Natural Science Foundation of China (Grant/Award Number: “81272581”).

Received January 18, 2016; Revised March 24, 2016; Accepted March 25, 2016

Cancer Sci 107 (2016) 836-845
doi: 10.1111/cas.12939

Pancreatic ductal adenocarcinoma (PDAC) is one of the most malignant tumors and is difficult to diagnose in the early phase. This study was aimed at obtaining the metabolic profiles and characteristic metabolites of pancreatic intraepithelial neoplasia (PanIN) and PDAC tissues from Sprague-Dawley (SD) rats to establish metabonomic methods used in the early diagnosis of PDAC. In the present study, the animal models were established by embedding 7,12-dimethylbenzanthracene (DMBA) in the pancreas of SD rats to obtain PanIN and PDAC tissues. After the preprocessing of tissues, 1H nuclear magnetic resonance (NMR) spectroscopy combined with multivariate and univariate statistical analysis was applied to identify the potential metabolic signatures and the corresponding metabolic pathways. Pattern recognition models were successfully established and differential metabolites, including glucose, amino acids, carboxylic acids and coenzymes, were screened out. Compared with the control, the trends in the variation of several metabolites were similar in both PanIN and PDAC. Kynurenate and methionine levels were elevated in PanIN but decreased in PDAC, thus, could served as biomarkers to distinguish PanIN from PDAC. Our results suggest that NMR-based techniques combined with multivariate statistical analysis can distinguish the metabolic differences among PanIN, PDAC and normal tissues, and, therefore, present a promising approach for physiopathologic metabolism investigations and early diagnoses of PDAC.

Pancreatic ductal adenocarcinoma (PDAC) is a highly malignant tumor with an extremely poor prognosis. Patients often have locally advanced unresectable PDAC or metastases when diagnosed. Only 10–20% of cases are resectable and the rate of 5-year survival is under 5.5%,1 making PDAC the fourth most common cause of death among tumors.2 Given the rapid progress of these tumors, early diagnosis of PDAC could significantly improve the prognosis. Previous study shows that patients with tumors <2 cm in diameter could have a 5-year survival rate as high as 30–60% while those with tumors <1 cm in diameter could have a 5-year survival rate of 75%, indicating that the therapeutic effect for patients with early PDAC is far better than for those with advanced lesions.3 Unfortunately, current diagnostic methods lack sensitivity and specificity to detect PDAC in the early stages. CA-199 is the most commonly used tumor marker in serum and displays a direct correlation with the occurrence and process of the disease.4 However, the sensitivity and specificity of diagnosis is only 59–64% to 69–82% when the dosage is 40–100 μ/mL, respectively.5 Image examinations also have some difficulties in PDAC diagnosis. Endoscopic ultrasonography-guided fine needle aspiration is an invasive examination that may lead to serious complications, while computed tomography and magnetic resonance imaging often fail to detect tumors under 2 cm in diameter. Therefore, there is a pressing need to develop a new diagnostic approach for early PDAC detection.

Nuclear magnetic resonance (NMR) spectroscopy is a highly sensitive and sophisticated technique used to analyze biochemical samples that can provide a wealth of metabolic information. The metabolic information is helpful in understanding the underlying metabolic mechanisms of diseases and establishing early diagnoses. NMR spectroscopy has been used in detecting the metabolic alterations in various types of cancers, including brain tumors, breast cancer and prostate cancer.6–10 Due to the fact that magnetic resonance spectroscopy (MRS) has been
recognized as a useful diagnostic method for detecting and identifying brain, breast and prostate cancers,\(^{(11)}\) increasing numbers of researchers have been looking at NMR-based metabolomic methods as promising in the clinical diagnosis of pancreatic cancer.\(^{(12-14)}\) Tesiram et al.\(^{(15)}\) report that total choline, taurine and glucose plus triglycerides were significantly increased in cancerous serum compared to controls. OuYang et al.\(^{(16)}\) observe remarkably lower levels of 3-hydroxybutyrate, 3-hydroxyisovalerate, lactate and trimethylamine-N-oxide and significant higher levels of isoleucine, triglyceride, leucine and creatinine in serum from pancreatic cancer patients compared with controls. Fang et al.\(^{(17)}\) compare the NMR spectra of pancreatic tissues from rat models of PDAC and controls, and show elevated levels of leucine, isoleucine, valine, alanine, lactate and taurine with decreased levels of betaine in pancreatic tissues of PDAC. These studies suggest the feasibility of using NMR spectroscopy to differentiate cancer from normal or other benign lesions.

Metabolomic analyses of both serum and pancreatic tissues from pancreatic intraepithelial neoplasia (PanIN) and PDAC are important for developing earlier diagnostic methods; however, the metabolomic information from tissues will be more favorable for the establishment of in vivo detection methods, such as \(^{1}H\) MRS, which will target at tumor tissue. Therefore, in this study, we aim to establish the metabolic profiles and characteristic metabolites of PDAC and PanIN, and evaluate the feasibility of NMR spectroscopy in early diagnosis of pancreatic cancer by comparing the NMR-based metabolic profiling of PanIN, PDAC and normal tissues in rat models.

Materials and Methods

Animal models. The animal experiments were conducted in the Experimental Animals Center of Fujian Medical University. The study protocol was in accordance with the principles of the National Institutes of Health guide for the care and use of Laboratory animals and approved by the Ethics Committee of the Fujian Medical University Union Hospital. Seventy-five male Sprague–Dawley (SD) rats (4–6 weeks old, weighing 150–170 g, obtained from the experimental animals center of Fujian Medical University, Fuzhou, China) were fed on standard laboratory conditions, and maintained at a temperature of 24 ± 2°C and a relative humidity of 50 ± 10%. SD rats were divided into three groups: experimental group I (n = 30), experimental group II (n = 30) and a control group (n = 15). The rats in the experimental groups were fasted for 12 h prior to surgery. The modeling started with a 2-cm transverse incision inferior to the xiphoid. Then, 7 mg of 7,12-Dimethylbenzanthracene (DMBA; Sigma-Aldrich, St Louis, MO, USA) was implanted under the capsule of the body and the tail of the pancreas. A purse string suture surrounding the embedding position of DMBA on pancreas was made to prevent leakage of the chemical powder. The incision was sutured and hemorrhages were staunched. Except that the DMBA was replaced by 7 mg of NaCl, the identical operation was carried out for the control group.

Tissue samples. Three weeks after embedding DMBA, the experimental group was killed while experimental group II and the control group were killed 12 weeks after surgery. During these procedures, all rats were on continuous airway anesthesia (Matrix, VMR, MIDMARK, USA) using isoflurane (Jiupei Pharmaceutical, Hubei, China, 2.5% gas concentration, 0.5 L/min). After the rats’ death, the pancreatic mass tissues were collected. For PanIN and PDAC tissues, the normal regions (which, visually, were not in accordance with the characteristic of tumorous lesions), were cleared off and confirmed by histological observation. The tissues collected were divided equally into two specimens: one for histological analysis and another for \(^{1}H\) NMR analyses. Then those samples for NMR analysis were quick-frozen in liquid nitrogen and stored at −80°C.

Histology of pancreatic samples. The samples for histology were fixed in 10% formalin solution for 12 h immediately after death. Paraaffin embedding and standard procedures followed, and 4-μm sections were made and stained with HE. All slices were randomly double-blind confirmed histologically by experienced pathologists. All PanIN cases (PanIN-1, 2 and 3) that occurred in experimental I were assigned to the PanIN group and all PDAC cases in experimental II were assigned to the PDAC group.

Sample preprocessing. Tissue samples (300 mg each) were defrosted on ice. The tissue was mixed with 0.6 mL ultrapure water and 1.2 mL methanol, and then homogenized for 3 min (MiniBeadbeater-16; BIO SPEC, Bartlesville, OK, USA) in 7-mL lap tubes. After the addition of 1.2 mL chloroform and 1.2 mL ultrapure water, the mixture was vortexed for 60 s. After 15 min standing, each sample was centrifuged at 10 397g for 10 min and the supernate was collected. Then, the supernate was lyophilized in vacuum freeze-drying equipment (Labconco Freeze-Dryer, Kansas City, MO, USA) for 24 h to eliminate water and methanol. For NMR analysis, the lyophilized was dissolved in 550 μL of 150-mM deuterated phosphate buffer (NaH₂PO₄ and K₂HPO₄, pH 7.4, including 0.1% sodium 3-[trimethylsilyl] propionate-2,2,3,3-d₄ (TSP)) followed with a 10 min centrifugation at 10 000 rpm. The 500-μL upper layer liquid was transferred into a 5-mm NMR tube for NMR analysis.

Nuclear magnetic resonance spectroscopy. \(^{1}H\) NMR spectroscopy was performed on aqueous extracts in the Varian NMR System (Agilent Technologies, Palo Alto, CA, USA) operating at 500.13 MHz proton frequency at 298 K. For each sample, spectra were acquired using the \(^{1}H\) NOESYPR1D pulse sequence with water suppression: RD-90°-t₁-90°-t₂-90°-ACQ. A total of 128 scans with a spectral width of 20 ppm, accompanied with a data point of 32 K, were collected for all spectra. The acquisition time was 1.36 s with a relaxation delay (RD) of 2 s, a fixed interval t₁ of 4 μs and the mixing time of 100 ms.

All free induction decays (FID) were multiplied by an exponential weighting function equivalent to a line-broadening of 1 Hz to increase the signal-to-noise ratio, followed by a Fourier transformation. All spectra were manually corrected for phase and baseline using MestReNova (V 9.0; Mestrelab Research, Santiago de Compostela, Galicia, Spain). The chemical shift in spectra was referenced to TSP at 80.0. The spectral regions 69.7–0.7 were integrally segmented into discrete regions of 0.002 ppm, and the spectral regions of 64.74–4.92 and 83.33–3.39 were removed to eliminate the interference of water and methanol signals for analysis. Then, the integrated data were normalized to a constant sum before multivariate statistical analysis.

Multivariate statistical analysis. Multivariate statistic analysis was performed using the software SIMCA-P+ (V11.0; Umetrics AB, Umeå, Sweden). Principal component analysis (PCA) was implemented using the approach of mean center scaling to simplify the multivariate data into a few principal components, which can highlight intrinsic trends and the existence of outliers. Partial least squares discriminant analysis (PLS-DA) and orthogonal partial least squares discriminant analysis (OPLS-DA) © 2016 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.
were included in the supervised pattern method to maximize the distinction between different groups in samples. Sequentially, these methods were carried out using Pareto scaling to discover the statistically significant metabolite variations in PDAC and PanIN groups. The results were visualized by using score plots and loading plots to highlight the group clusters and variates, respectively. Then the model coefficients were back-calculated from the coefficients incorporating the weight of the variables and plotted with color-coded coefficients to enhance the interpretability of the models. Thus, the metabolic components that contributed to the variation between groups could be displayed and extracted from the color-coded loading plots. The coefficient plots were color-coded according to the absolute value of coefficients, with a hot color corresponding to a significant difference between classes and a cool color corresponding to no significant differences. Based on significance at $P < 0.05$ and degree of freedom $= 10$, the correlation coefficient $|r| > 0.576$ was set to the cut-off value, which was determined by the test for the significance of Pearson’s correlation coefficient. In addition, through 10-fold cross-validation and the response permutation testing (RPT, permutation number = 200), the quality and validity of PLS-DA pattern recognition models could be fully assessed. The cross-validation parameters $R^2$ and $Q^2$ in the permuted plot represent the degree of model fitting and the predictive ability of the derived models, respectively. If the maximum value of $Q^2$ from the permutation test is not more than the $Q^2$ of the real model, the model could serve as a predictable model.

**Univariate statistical analysis.** The relative concentrations of those metabolites with discriminatory significance derived from multivariate statistical analysis were calculated by integrating their characteristic signals in the NMR spectra. A one-way ANOVA was performed by using Students’ $t$-test (SPSS, version 19.0; IBM SPSS, Chicago, IL, USA) to statistically confirm the differences in metabolite levels among different groups. The relative concentration was expressed as means ± SD, and a $P$-value $< 0.05$ was considered as statistically significant.

**Results**

**Animal models and the corresponding $^1$H nuclear magnetic resonance spectra from pancreatic tissues.** To investigate the metabolic alteration in each phase of PDAC, we used the rats

![Fig. 1. (HE ×400) Representative histology of pancreatic tissues from DMBA-treated Sprague-Dawley rats. (a) Histological section of the pancreas with the pancreatic intraepithelial neoplasia (PanIN)-II lesion (arrow) demonstrates small papillae of lesion and mild-to-moderate nucleic abnormalities, including some loss of polarity, enlarged nuclei and pseudostratification. (b) Histological section of the pancreas with the PDAC lesion (arrow).](image)

![Fig. 2. (d) Representative 500 MHz 1H NOESYPR1D nuclear magnetic resonance (NMR) spectra (δ0.7–5.3 and δ5.3–9.7) from the aqueous extracts of (a) control, (b) pancreatic intraepithelial neoplasia and (c) pancreatic ductal adenocarcinoma pancreatic tissues. The spectral regions of δ5.3–9.7 (in the dashed box) were magnified 10 times compared with the regions of δ0.7–5.3 for the purpose of clarity. The assignments of peaks were noted. 3-HB, 3-Hydroxybutyrate; 2-HB, 2-Hydroxybutyrate; 3-MH, 3-Methylhistidine; 1-MH, 1-Methylhistidine; 3-MX, 3-Methylxanthine; Ace, acetate; Ach, acetylcholine; Act, acetone; Ads, adenosine; ADP, adenosine 3',5'-diphosphate; AMP, adenosine monophosphate; ATP, adenosine triphosphate; Adp, adipate; Ala, alanine; Alt, allantoin; All, allantoic acid; ζ-Glc, ζ-Glucose; Asc, ascorbate; Asp, aspartate; β-Glc, β-Glucose; Bet, betaine; Cho, choline; Cl, chloride; Cit, citrate; Cr, creatine; Ctd, cytidine; DMG, dimethylglycine; Eth, ethanol; EA, ethanolamine; Fmd, formaldehyde; For, formate; Fum, fumarate; G, glyceraldehyde; Gin, glutamine; Glu, glutamate; GPC, glycerolphosphocholine; Gly, glycine; Ino, inosine; Ile, isoleucine; KA, kynurenate; Lac, lactate; Leu, leucine; Lys, lysine; Met, methionine; MM, methylmalonate; m-I, myo-Inositol; NA, nicotinamide; NAD, nicotinamide adenine dinucleotide; NADP, nicotinamide adenine dinucleotide phosphate; PC, phosphocholine; Phe, phenylalanine; Ppy, phosphoenolpyruvate; Py, pyruvate; Sar, sarcosine; Suc, succinate; Tau, taurine; Tig, tiglicnate; TMA, trimethylamine; Tyr, tyrosine; Uc, uracil; Ud, uridine; UDG, uridine diphosphate glucose; Val, valine; VK, vitamin K.)**

© 2016 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.
embedded with DMAB to induce PanIN and PDAC. Confirmed by histological observation (Fig. 1), PanIN (PanIN-2, \( n = 11 \)), PDAC (\( n = 15 \)) and control (\( n = 14 \)) rats were included in NMR detections. Typical 500-MHz \(^1\)H NMR spectra of aqueous pancreas extracts from each group are presented in Figure 2. The resonance assignment and metabolite identification for these extracts were conducted based on the previous literature and public databases.\(^\text{18,19}\) These one-dimensional NMR spectra, including 64 metabolites (Fig. 2), could provide a rough overview of all metabolites. A certain degree of metabolic differences on the spectra could be noticed between control, PanIN and PDAC (e.g. lactate, vitamin K and betaine). Due to the high similarity of the NMR spectra on visual inspection, the acquisition of differential metabolites information is limited. Thus, to obtain more precise and detailed information, multivariate statistical analysis was implemented on NMR spectral data.

**Metabonomic profile of normal, PanIN and PDAC rats.** Principal component analysis was performed to provide an overview of the \(^1\)H NMR data collected from aqueous extracts of the control, PanIN and PDAC pancreatic tissues. As the score plots reveal (Fig. 3a), the first two principal components (PC1 and PC2) could explain 67.4% of the total variance and no outlier was found. A certain degree of separation existed between the control group and PanIN and PDAC groups in the PCA score plot; however, PanIN and PDAC groups were mixed with each other due to their similar metabolic profiles. Therefore, PLS-DA was performed on these three groups to further maximize the systematic variance and to eliminate the interference information. On visual inspection, the separation in the PLS-DA score plot (Fig. 3b) was much more obvious than for PCA. However, a moderate overlap can still be observed between PanIN and PDAC groups, indicating that the metabolic alterations that occurred in the lesions were similar in a certain degree.

Partial least squares discriminant analysis was also performed on groups in pairs (control vs PanIN, control vs PDAC, PanIN vs PDAC). Pronounced separations can be observed in all three plots (Fig. 4a), which represent the discriminating metabolic profile between pair-wise groups. According to the cross-validation parameters, \( R^2 \) (the total explained variation) and \( Q^2 \) (the predictability of the models) (Fig. 4, left panels), for all three models demonstrate strong predictability and reliable subsequent identification of the characteristic metabolites. The validation plots from permutation tests (Fig. 4, right panels) and 10-fold cross-validation suggested that the models based on the NMR data from aqueous extracts were effective and authentic. In addition, the smaller \( R^2 \) and \( Q^2 \) values in the PanIN versus PDAC model than in others and a little overfitting in this model (Fig. 4c) also indicated similar metabolic profiles and the continuity of the physiological changes from PanIN to PDAC.

To understand the detailed metabolic information following the progress of the disease and to identify the metabolites responsible for the metabonomic differences, OPLS-DA was also conducted on the NMR data among normal, PanIN and PDAC groups for one predictive component and one orthogonal component (Fig. 5). The score plots demonstrate the obvious distinctions between pair-wise groups (Fig. 5, left panel), while the loading plots with color-coded correlation coefficients could clearly display the metabolites contributed to metabonomic difference in each pair-comparison (Fig. 5, middle and right panels). Finally, 37 of the characteristic metabolites and their corresponding variations in PanIN and PDAC groups were identified and their differences in relative concentrations among different groups were confirmed by univariate statistical analysis (Table 1). Only a few results from univariate statistical analysis were different from those from OPLS-DA, including acetylcholine, aspartate, lysine, NADP\(^+\) and nicotinamide, which could be due to the very low level of metabolites, the statistical difference between multivariate and univariate analysis, and the possible overlap between signals from different metabolites in

![Fig. 3.](image-url) (a) Principal component analysis scores plot based on 1H NOESYPR1D nuclear magnetic resonance (NMR) spectra of control (■), pancreatic intraepithelial neoplasia (PanIN) (♦), PDAC (▲). (b) PLS-DA scores plot based on 1H NOESYPR1D NMR spectra of control (■), PanIN (♦), PDAC (▲).
NMR spectra, thus demonstrating a high reliability of multivariate statistical analysis. Metabonomic pathways analysis was conducted using the KEGG database. The primary pathways correlate to characteristic metabolites of PanIN and PDAC, and the numbers of common tendency metabolites involved in corresponding pathways are listed in Table 2.

Fig. 4. PLS-DA scores plots (left panels) and plots of permutation tests (n = 200) of PLS-DA (right panels) based on 1H NOESYPR1D nuclear magnetic resonance (NMR) spectra of aqueous extracts from normal Sprague-Dawley (SD) rat pancreas (control, black box ■), pancreatic intraepithelial neoplasia (pancreatic intraepithelial neoplasia [PanIN], green diamond ■) and SD rat pancreatic ductal adenocarcinoma (pancreatic ductal adenocarcinoma [PDAC], blue triangle ▲). (a) Control versus PanIN; (b) control versus PDAC; (c) PanIN versus PDAC.
Discussion

To meet the need for early diagnosis of PDAC, various methods have been used to find corresponding biomarkers. NMR spectroscopy demonstrates advantages over other detection methods as a noninvasive and effective tool for the identification of characteristic metabolites. In this study, DMBA was implanted in the pancreas of SD rats to establish animal PanIN and PDAC models. This chemical could induce a series of pathological changes from the healthy state to PDAC with different induction times, thus simulating the progress of PDAC in humans. Because the tissue of PanIN is often too small to dissect from non-tumor regions, metabonomic information on non-tumor regions could interfere the identification of metabolite biomarkers, which may exert an influence on the sensitivity of NMR spectroscopy analysis. Nonetheless, a rigorous sampling process and histological diagnoses were conducted to...
Table 1. OPLS-DA coefficients and relative concentrations of metabolites derived from the nuclear magnetic resonance data in different groups

| Metabolites         | C-PanIN  | C-PDAC   | PanIN-PDAC | C      | PanIN   | PDAC    |
|---------------------|----------|----------|------------|--------|---------|---------|
| 1-Methylhistidine   | 0.718    | —        | —0.771     | 0.48   | 1.25    | 0.57    |
| 2-Hydroxybutyrate   | 0.750    | 0.701    | —          | 1.18   | 2.07    | 2.07    |
| 3-Hydroxybutyrate   | 0.912    | 0.612    | —0.728     | 0.42   | 0.80    | 0.61    |
| 3-Methylhistidine   | −0.775   | −0.753   | —          | 0.42   | 0.25    | 0.26    |
| Acetate             | 0.793    | 0.657    | −0.730     | 0.77   | 1.23    | 1.04    |
| Acetylcholine       | −0.673   | —        | 0.643      | 3.24   | 2.20    | 2.86    |
| Adenosine           | −0.578   | −0.651   | −0.712     | 1.71   | 1.17    | 1.07    |
| Adipate             | 0.711    | —        | −0.698     | 1.01   | 2.56    | 1.28    |
| Ascorbate           | —        | 0.764    | 0.708      | 26.11  | 26.74   | 29.37   |
| Aspartate           | −0.900   | −0.745   | 0.796      | 21.10  | 16.32   | 20.24   |
| Betaine             | −0.916   | −0.654   | —          | 12.72  | 8.99    | 10.90   |
| Citrate             | 0.861    | —        | −0.713     | 0.89   | 1.64    | 0.94    |
| Creatine            | −0.936   | —        | 0.844      | 2.90   | 2.45    | 2.79    |
| Cytidine            | −0.859   | −0.791   | −0.688     | 3.26   | 1.78    | 1.88    |
| Dimethylglycine     | 0.797    | —        | −0.710     | 0.03   | 0.09    | 0.03    |
| Glutamate           | 0.726    | 0.586    | —          | 11.43  | 12.55   | 12.33   |
| Glycerol            | —        | 0.715    | 0.607      | 39.15  | 37.56   | 42.70   |
| Inosine             | −0.780   | −0.591   | —0.796     | 1.75   | 0.85    | 1.21    |
| Isoleucine          | 0.730    | 0.772    | —          | 0.47   | 0.72    | 0.79    |
| Kynurenine          | 0.629    | −0.719   | −0.725     | 1.88   | 2.26    | 1.53    |
| Lactate             | 0.725    | 0.686    | −0.582     | 8.42   | 15.43   | 14.41   |
| Leucine             | 0.780    | 0.761    | —          | 1.55   | 1.73    | 2.03    |
| Lysine              | 0.852    | —        | −0.665     | 5.45   | 7.25    | 5.69    |
| Methionine          | 0.874    | −0.620   | −0.645     | 1.03   | 1.33    | 0.92    |
| myo-Inositol        | 0.591    | 0.730    | —          | 7.67   | 8.36    | 8.67    |
| Nicotinamide        | −0.851   | −0.825   | −0.740     | 0.30   | 0.26    | 0.32    |
| NAD+                | −0.941   | −0.766   | —          | 0.05   | 0.02    | 0.02    |
| NADP+               | −0.779   | −0.804   | −0.750     | 0.02   | 0.01    | 0.02    |
| Phenylalanine       | 0.622    | 0.777    | —          | 0.35   | 0.55    | 0.64    |
| Sarcosine           | 0.746    | —        | −0.761     | 0.10   | 0.21    | 0.06    |
| Taurine             | —        | 0.768    | 0.706      | 9.64   | 11.47   | 15.87   |
| Uracil              | −0.793   | −0.743   | −0.810     | 1.36   | 0.98    | 0.85    |
| Uridine             | −0.907   | −0.739   | −0.749     | 5.77   | 3.38    | 3.77    |
| Uridine diphosphate | −0.817   | −0.810   | —          | 4.01   | 2.16    | 2.08    |
| Valine              | 0.734    | 0.753    | —          | 0.85   | 1.24    | 1.27    |
| Vitamin K           | −0.904   | −0.850   | —          | 5.28   | 2.26    | 3.01    |
| α-Glucose           | —        | 0.732    | 0.659      | 2.31   | 3.13    | 4.85    |

†Correlation coefficients: positive and negative signs indicate positive and negative correlation in the concentrations. |r| > 0.576 is the cut-off value for significance based on significance of P = 0.05 and degrees of freedom = 10. "—" means |r| < 0.576. ‡Relative concentration derived by integrating the characteristic signals of each metabolite in the nuclear magnetic resonance spectra, and the concentrations are expressed as means ± SD. *P < 0.05, **P < 0.01, ***P < 0.001 versus control group; #P < 0.05, ##P < 0.01, ###P < 0.001 versus PanIN group. C, control group. PanIN, pancreatic intraepithelial neoplasia; PDAC, pancreatic ductal adenocarcinoma.
...and migration of PDAC. (31) Meanwhile, the metabolic pionic acid, as a result, to be a switch to increase the chance aspartate and alpha-amino-3-hydroxy-5-methyl-4-isoxazolepro-
tumor necrosis factor-alpha converting enzyme and resulted an 
cellular transformation, which caused the inactivation of the 
leucine, isoleucine and valine, may be tightly connected with 
myo...through tricarboxylic acid circle and the glutamate plays an 
which is one of the most significant mechanisms to promote 
metabolic phenomenon associated with reconstructed glutamine metabolism, 
tissue. To date, few metabonomic studies have been conducted 
metabolic variations relevant to PanIN. In the 
the present study, obvious metabolic alterations in both 
alpha-ketoacidopathies and the oncogenes of Ras, PI3K, 
metabolism, which involved abnormal concentration changes of glutamate, aspartate, 
metabolism, including in glucose, amino acids, carboxylic acids and coen-
way of central carbon metabolism in cancer, which involved 
low concentration of glutamate and increased concentration of glutamine in tissue were a significant phe-
...metabolic differences in PanIN compared with the normal 
tissue. To date, few metabonomic studies have been conducted 
to investigate the metabolic variations relevant to PanIN. In the 
the present study, obvious metabolic alterations in both PanIN and PDAC compared to control groups were observed, 
including in glucose, amino acids, carboxylic acids and coen-
zymes (Table 1). With the KEGG pathway analysis, the pathway 
cancer and the corresponding metabolites could be valuable for the metabonomic-based detection and diagnosis of PanIN.

**Metabonomic difference in PanIN compared with pancreatic ductal adenocarcinoma.** In previous reports, higher concentrations of taurine, glutamate, lactate, leucine, isoleucine and valine and lower concentration of betaine were identified as biomarkers in PDAC tissue,(17,34) which were also observed in the present study. It is meaningful to find those with the same trends in the variation of PanIN, which may serve as biomarkers not only for PDAC but also for pancreatic precancerous lesions. Furthermore, acknowledging the metabolic difference 
common variation tendency in all significant metabolites which are involved in corresponding pathways in pairwise groups of control-
pancreatic intraepithelial neoplasia (PanIN) and control-pancreatic ductal adenocarcinoma (PDAC).

because the former are more conductive to screen out the character-
this trend in variation and relevant pathways (Table 2), such as the metabolism of glycolysis, amino acids, nucleic acid and nicotinamide, which are important components in tumor metabolism.(35–37) This discovery can be interpreted as the intercommunity and continuity of metabolic abnormality from PanIN to PDAC and regarded as indirect evidence of PDAC’s genealogical theory,(21,22) thus implying the feasibility to diagnose PanIN and PDAC based on similar mutual metabolite clusters. Only kynurenate and methionine showed a difference in the trends in variation, which were increased in PanIN but decreased in the PDAC. Considering being a crucial participant in tryptophan metabolism, the content variation of kynurenate can be associated with the disorder of tryptophan metabolism which can further affect the nicotinamide metabolism and gly-
colysis. In addition, its abnormal concentration was reported to be associated with inflammation that contributed to tumorgenesis.(38,39) Methionine is on the central position in the methionine cycle and the most important methyl donor for synthesis of nitrogen substances. Because the methionine and tryptophan are transported into the cancer cells by the L-type amino-acid transporter 1 (LAT1), which has been proved to be overexpressed in the PDAC and is highly related to patients’ prognosis,(40) it is reasonable to speculate that molecular events along with the progression from PanIN to PDAC may impact on LAT1 and cause these differential metabolic variations in the two lesions. In addition, the high level of dimethylglycine and sarcosine in PanIN can be correlated with the enhanced biosynthesis of serine, gly-
cine and cysteine, which are significant for growth and proliferation of cancer cells. Moreover, the high level of taurine in PDAC was in accordance with the previous report(23) but different in PanIN, Taurine is an organic acid highly collected in immune cells(41,42) and proved to be associated with apoptosis(43,44) reflecting the body’s immune response toward the tumorgenesis. Because modeling and preprocessing procedures are different, it is still debatable to determine the content alterations of taurine in PanIN.

To sum up, we utilized an NMR-based metabonomic technique to demonstrate that significant metabolic changes occur

| Pathways                                      | Control-PanIN† | Control-PDAC‡ | Common tendency‡ |
|-----------------------------------------------|----------------|---------------|------------------|
| Biosynthesis of antibiotics                   | 10/32          | 9/31          | 8/10             |
| ABC transporters                              | 9/32           | 11/31         | 8/12             |
| Central carbon metabolism in cancer           | 8/32           | 8/31          | 7/9              |
| 2-Oxocarboxylic acid metabolism               | 8/32           | 6/31          | 6/8              |
| Biosynthesis of amino acids                   | 8/32           | 7/31          | 5/9              |
| Protein digestion and absorption              | 8/32           | 8/31          | 6/10             |
| Aminoacyl-tRNA biosynthesis                   | 7/31           | 7/31          | 6/7              |
| Pyrimidine metabolism                         | 4/32           | 4/31          | 4/4              |
| Nicotinate and nicotinamide                   | 4/32           | 4/31          | 4/4              |
| Other specific amino acid                     | 11/32          | 9/31          | 8/11             |

†For each pathway, the ratio of metabolites involved in any metabolic pathway to all significant metabolites corresponding to the pairwise group difference. †For each pathway, the ratio of metabolites with common variation tendency in all significant metabolites which are involved in corresponding pathways in pairwise groups of control-
PanIN and control-pancreatic ductal adenocarcinoma (PDAC).
in glucose, amino acids and carboxylic acids in PanIN and PDAC tissues, which were involved in the tumor metabolism reprogramming. Although trends in the variation of metabolites in PanIN and PDAC were similar compared with normal pancreas tissues, the metabolic differences were obvious enough to distinguish PanIN from not only the control but also PDAC. The specific metabolic biomarkers of PanIN were identified and recognition models of pair-comparisons were established with considerable sensitivity and specificity, which can aid in establishing noninvasive metabolic diagnostic methods to distinguish PDAC and PanIN from normal pancreas tissues in the future. NMR-based metabolomic strategies present a promising approach for metabolism investigations and early diagnosis of PanIN and PDAC.

Acknowledgments

This work is sponsored by the National Natural Science Foundation of China (No. 81272581), the United Fujian Provincial Health and Education Project for Tackling the Key Research (No. WKJ-FJ-10) and the National Key Clinical Speciality Discipline Construction Program of China and Key Clinical Speciality Discipline Construction Program of Fujian.

Disclosure Statement

All the authors declare no conflict of interest and all the authors have not financial or personal relationships with other people or organization that could inappropriately influence this work.

References

1. Matsuda T, Marugame T, Kamo K et al. Cancer incidence and incidence rates in Japan in 2005: based on data from 12 population-based cancer registries in the Monitoring of Cancer Incidence in Japan (MCIJ) project. Jpn J Clin Oncol 2011; 41: 139–47.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10–29.
3. Chari ST. Detecting early pancreatic cancer: problems and prospects. Semin Oncol 2007; 34: 284–94.
4. Kokhanenko N, Ignashov AM, Varga EV et al. Role of the tumor markers CA 19-9 and carcinoembryonic antigen (CEA) in diagnosis, treatment and prognosis of pancreatic cancer. Vopr Onkol 2001; 47: 294–7.
5. Singh S, Tang SJ, Streanarasimaiah J, Lara LF, Siddiqui A. The clinical utility and limitations of serum carbohydrate antigen (CA19-9) as a diagnostic tool for pancreatic cancer and cholangiocarcinoma. Dig Dis Sci 2011; 56: 2491–6.
6. Rehman L, Rehman UL, Azmat SK, Mohammad Hashim AS. Magnetic resonance imaging and magnetic res- onance spectroscopy in the Monitoring of Cancer Incidence in Japan (MCIJ) project. Jpn J Cancer Res Treat 2010; 101: 1483–5.
7. Sipos B, Frank S, Gress T, Hahn S, Kloppel G. Pancreatic intraepithelial neoplasia revisited and updated. Pancreatology 2009; 9: 45–54.
8. Jensen SK. Improved Bligh and Dyer extraction procedure. Lipid Technol 2000; 12: 280–1.
9. Cheng LL, Lean CL, Bogdanova A et al. Enhanced resolution of proton NMR spectra of malignant lymph nodes using magic-angle spinning. Magn Reson Med 1996; 36: 653–8.
10. Cogliuzzi CE, Nachreiner CE, Vila AM. Detection of pancreatic cancer using 1H nuclear magnetic resonance spectroscopy. J Magn Reson Imaging 2003; 17: 733–8.
11. Lin J, Zuo H, Guo X et al. Distinguishing pancreatic cancer from chronic pancreatitis and healthy individuals by H-1 nuclear magnetic resonance-based metabolic profiles. Clin Biochem 2012; 45: 1064–9.
12. Nicolaides C, Sperandio N, Lawlor RT, Scarpas A, Molinari H, Assfalg M. Glutamate increases pancre- atic cancer cell invasion and migration via AMPA receptor activation and K+ channel-dependent mechanisms. Pancreas 2015; 44: 863–73.
13. Wishart DS, Knox C, Guo AC et al. HMDB: a knowledgebase for the human metabolome. Nucleic Acids Res 2009; 37: D603–10.
14. Napoli C, Sperandio N, Lawlor RT, Scarpa A, Molinari H, Assfalg M. Urine metabolic profiling of patients with chronic pancreatitis. J Transl Med 2013; 11: 1274–83.
15. Tesiram YA, Lerner M, Stewart C, Njoku C, Brackett DJ. Utility of nuclear magnetic resonance spectroscopy for pancreatic cancer studies. Pancreas 2012; 41: 474–80.
16. OuYang D, Xu J, Huang H, Chen Z. Metabolomic profiling of serum from healthy pancreas patients using 1H NMR spectroscopy and principal component analysis. Appl Biochem Biotechnol 2011; 165: 148–54.
17. Fang F, He X, Deng H et al. Discrimination of metabolic profiles of pancreatic cancer from chronic pancreatitis by high-resolution magic angle spinning (1H) nuclear magnetic resonance and principal components analysis. Cancer Sci 2007; 98: 1678–82.
18. Cui Q, Lewis IA, Hegeman AD et al. Metabolite identification by the Madison Metabolomics Consortium Database. Nat Biotechnol 2008; 26: 162–4.
Kairaka, Sunose Y, Arakawa K et al. Prognostic significance of L-type amino-acid transporter 1 expression in surgically resected pancreatic cancer. *Br J Cancer* 2012; 107: 632–8.

Dingley AJ, King NJ, King GF. An NMR investigation of the changes in plasma membrane triglyceride and phospholipid precursors during the activation of T-lymphocytes. *Biochemistry* 1992; 31: 9098–106.

Wright LC, Obbink KL, Delikatny EJ, Santangelo RT, Sorrell TC. The origin of 1H NMR-visible triacylglycerol in human neutrophils. High fatty acid environments result in preferential sequestration of palmitic acid into plasma membrane triacylglycerol. *Eur J Biochem* 2000; 267: 68–78.

Opstad KS, Bell BA, Griffiths JR, Howe FA. Taurine: a potential marker of apoptosis in gliomas. *Br J Cancer* 2009; 100: 789–94.

Zhang X, Tu S, Wang Y, Xu B, Wan F. Mechanism of taurine-induced apoptosis in human colon cancer cells. *Acta Biochim Biophys Sin* 2014; 46: 261–72.